0
ARTICLE |

FATALITIES ASSOCIATED WITH ANALBIS SUPPOSITORIES

Israel Weinstein, M.D.
JAMA. 1947;133(13):962-963. doi:10.1001/jama.1947.02880130062022.
Text Size: A A A
Published online

ABSTRACT

To the Editor:—  This is a preliminary report on fatalities associated with the use of suppositories of a bismuth salt of heptadienecarboxylic acid (diallyl acetic acid), marketed as "Analbis" and manufactured and sold by Specific Pharmaceuticals, Inc., of New York City.The drug has been used for the past ten years in various European countries, particularly Hungary and France, for the alleviation of symptoms in acute inflammations of the throat, and preoperatively in tonsillectomies. In October 1943 the manufacturer made application to the Federal Food and Drug Administration for permission to manufacture and sell Analbis suppositories. The drug was widely distributed throughout the United States. It was also sold in Canada, Mexico, Puerto Rico, Cuba, Brazil and China. It is not included in New and Nonofficial Remedies, the official publication of the Council on Pharmacy and Chemistry of the American Medical Association. Several articles have appeared indicating its effectiveness in

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs